Generic drug
Abacavir / lamivudine price, strengths & recalls
Pharmacies pay $42.94 for 30 tablets of Abacavir / lamivudine 600 mg / 300 mg tablet this week. 5 manufacturers make it. Its official label last changed on September 21, 2026.
Generic- Fair cash price
- $59.88
- Strengths
- 1
- Makers
- 5
- Updated
- Nov 11
Abacavir / lamivudine price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 600 mg / 300 mg tablet | $1.43 | $42.94 / 30 tablets |
Supply status: shortages & recalls
What people paid for Abacavir / lamivudine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ABACAVIR AND LAMIVUDINE TABLETS safely and effectively. See full prescribing information for ABACAVIR AND LAMIVUDINE TABLETS. ABACAVIR and LAMIVUDINE tablets, for oral use Initial U.S. Approval: 2004
WARNING: HYPERSENSITIVITY REACTIONS and EXACERBATIONS OF HEPATITIS B
Hypersensitivity Reactions
Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of abacavir and lamivudine. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele [see Warnings and Precautions (5.1)].
Abacavir and lamivudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients [see Contraindications (4), Warnings and Precautions (5.1)]. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir and lamivudine or reinitiation of therapy with abacavir and lamivudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir and lamivudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see Contraindications (4), Warnings and Precautions (5.1)].
Following a hypersensitivity reaction to abacavir and lamivudine, NEVER restart abacavir and lamivudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see Warnings and Precautions (5.1)].
Exacerbations of Hepatitis B
Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine, which is a component of abacavir and lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir and lamivudine and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.2)].
WARNING: HYPERSENSITIVITY REACTIONS and EXACERBATIONS OF HEPATITIS B
See full prescribing information for complete boxed warning.
Hypersensitivity Reactions
● Serious and sometimes fatal hypersensitivity reactions have occurred with abacavir-containing products. (5.1)
● Hypersensitivity to abacavir is a multi-organ clinical syndrome. (5.1)
● Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a hypersensitivity reaction to abacavir. (5.1)
● Abacavir and lamivudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. (4)
● Discontinue abacavir and lamivudine as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue abacavir and lamivudine if hypersensitivity cannot be ruled out, even when other diagnoses are possible. (5.1)
● Following a hypersensitivity reaction to abacavir and lamivudine, NEVER restart abacavir and lamivudine or any other abacavir-containing product. (5.1)
Exacerbations of Hepatitis B
● Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine, a component of abacavir and lamivudine. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (5.2)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 5 approved generic applications on the market
Abacavir / lamivudine questions
How much does abacavir / lamivudine cost without insurance?
Pharmacies pay about $42.94 for 30 tablets of abacavir / lamivudine 600 mg / 300 mg tablet ($1.43 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $59.88. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is abacavir / lamivudine in shortage?
No shortage is reported for abacavir / lamivudine right now. We check the national shortage list every day.
Has abacavir / lamivudine been recalled?
No recalls are on record for abacavir / lamivudine.
When did the abacavir / lamivudine label last change?
The official label was last updated on September 21, 2026 (version 5). See what changed.
Talk about abacavir / lamivudine
No comments yet. Questions, tips, what worked for you - start the conversation.